These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35765514)

  • 1. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection.
    Bajpai J; Pradhan A; Verma AK; Kant S
    World J Exp Med; 2022 May; 12(3):44-52. PubMed ID: 35765514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
    Damle B; Vourvahis M; Wang E; Leaney J; Corrigan B
    Clin Pharmacol Ther; 2020 Aug; 108(2):201-211. PubMed ID: 32302411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.
    Okada JI; Yoshinaga T; Washio T; Sawada K; Sugiura S; Hisada T
    Clin Transl Sci; 2021 May; 14(3):1092-1100. PubMed ID: 33404133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
    Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB;
    Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
    Pani A; Lauriola M; Romandini A; Scaglione F
    Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis.
    Budhathoki P; Shrestha DB; Khadka S; Rawal E
    J Nepal Health Res Counc; 2021 Apr; 19(1):1-9. PubMed ID: 33934125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges.
    Abou Warda AE; Tammam M; El-Gazar RA; Sarhan RM; Gaber S
    Curr Drug Saf; 2022; 17(2):143-151. PubMed ID: 34315385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
    Medina MT; Moncada SS
    J Neurol Sci; 2020 Aug; 415():116972. PubMed ID: 32534369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19.
    Shahsavarinia K; Ghojazadeh M; Ghabousian A; Hatefnia F; Soleimanpour M; Soleimanpour H
    Anesth Pain Med; 2021 Aug; 11(4):e115827. PubMed ID: 34692436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
    Szendrey M; Guo J; Li W; Yang T; Zhang S
    J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Shah RR
    J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19.
    Fox MP; D'Agostino McGowan L; James BD; Lessler J; Mehta SH; Murray EJ
    Am J Epidemiol; 2021 Apr; 190(4):491-495. PubMed ID: 32860038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Hydroxychloroquine and Azithromycin Combination Use in COVID-19 Patients - An Umbrella Review.
    Nag K; Tripura K; Datta A; Karmakar N; Singh M; Singh M; Singal K; Pradhan P
    Indian J Community Med; 2024; 49(1):22-27. PubMed ID: 38425958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.